Literature DB >> 8627804

In vivo model of adeno-associated virus vector persistence and rescue.

S A Afione1, C K Conrad, W G Kearns, S Chunduru, R Adams, T C Reynolds, W B Guggino, G R Cutting, B J Carter, T R Flotte.   

Abstract

Gene therapy vectors based on human DNA viruses could be mobilized or rescued from individuals who are subsequently infected with the corresponding wild-type (wt) helper viruses. This phenomenon has been effectively modeled in vitro with both adenovirus (Ad) and adeno-associated virus (AAV) vectors but has not previously been studied in vivo. In the current study, we have developed an in vivo model to study the interactions of a recombinant AAV vector (AAV-CFTR) with wt AAV type 2 (AAV2) and a host range mutant Ad (Ad2HR405) for which monkey cells are permissive (D.E.Brough, S.A.Rice, S.Sell, and D.F.Klessig, J. Virol. 55:206-212, 1985). AAV-CFTR was administered to the respiratory epithelium of the nose or lung of rhesus macaques. Primary cells were harvested from the infusion site at time points up to 3 months after vector administration to confirm vector DNA persistence. Vector DNA was present in episomal form and could be rescued in vitro only by addition of wt AAV2 and Ad. In in vivo rescue studies, vector was administered before or after wt-AAV2 and Ad2HR405 infection, and the shedding of AAV-CFTR was examined. Ad2HR405 and wt-AAV2 infections were established in the nose with concomitant administration. wt-AAV2 replication occurred in the lung when virus was administered directly at a high titer to the lower respiratory tract. AAV-CFTR vector rescue was also observed in the latter setting. Although these studies were performed with small numbers of animals within each group, it appears that AAV-CFTR DNA persists in the primate respiratory tract and that this model may be useful for studies of recombinant AAV vector rescue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627804      PMCID: PMC190187     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.

Authors:  R G Crystal; N G McElvaney; M A Rosenfeld; C S Chu; A Mastrangeli; J G Hay; S L Brody; H A Jaffe; N T Eissa; C Danel
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

2.  Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo.

Authors:  M A Rosenfeld; W Siegfried; K Yoshimura; K Yoneyama; M Fukayama; L E Stier; P K Pääkkö; P Gilardi; L D Stratford-Perricaudet; M Perricaudet
Journal:  Science       Date:  1991-04-19       Impact factor: 47.728

3.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.

Authors:  J Zabner; L A Couture; R J Gregory; S M Graham; A E Smith; M J Welsh
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

5.  Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.

Authors:  R M Kotin; J C Menninger; D C Ward; K I Berns
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

6.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

Review 7.  Adeno-associated virus: integration at a specific chromosomal locus.

Authors:  R J Samulski
Journal:  Curr Opin Genet Dev       Date:  1993-02       Impact factor: 5.578

8.  Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.

Authors:  T R Flotte; S A Afione; R Solow; M L Drumm; D Markakis; W B Guggino; P L Zeitlin; B J Carter
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

9.  Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination.

Authors:  R M Kotin; R M Linden; K I Berns
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  Targeted integration of adeno-associated virus (AAV) into human chromosome 19.

Authors:  R J Samulski; X Zhu; X Xiao; J D Brook; D E Housman; N Epstein; L A Hunter
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  62 in total

1.  Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination.

Authors:  J Yang; W Zhou; Y Zhang; T Zidon; T Ritchie; J F Engelhardt
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 2.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

3.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

Review 6.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

Review 7.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

8.  A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.

Authors:  William B Guggino; Janet Benson; JeanClare Seagrave; Ziying Yan; John Engelhardt; Guangping Gao; Thomas J Conlon; Liudmila Cebotaru
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

9.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors.

Authors:  S Song; M Morgan; T Ellis; A Poirier; K Chesnut; J Wang; M Brantly; N Muzyczka; B J Byrne; M Atkinson; T R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 10.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.